CRED 8 Presentations

01/07/2024

Exceptional circumstances cf. conditional marketing authorisation

• Conditional marketing authorisation • Demonstrate positive benefit risk balance, based on scientific data, pending confirmation • MA valid for one year, on a renewable basis • Once pending studies are provided, converted to "normal" MA

Exceptional circumstances • Comprehensive data cannot be provided (specific reasons foreseen in legislation) • Reviewed annually to reassess the risk-benefit balance • Will normally not lead to the completion of the dossier and "normal" MA

The Organisation for Professionals in Regulatory Affairs

37

Other EU Key Strategic Considerations

Orphan drug considerations

Risk Management Plan

• Paediatric investigation plans (PIPs)

• Non-NCEs and legal basis of application • Pharmacovigilance system master file (PSMF)

Scientific advice

PRIME

Managing Internal/External Expectations

The Organisation for Professionals in Regulatory Affairs

38

Made with FlippingBook Ebook Creator